February 1, 2017
Kyowa Hakko Kirin said on January 31 that it has established a new company, Kyowa Kirin Frontier, which will be working to obtain Japanese regulatory approval for an authorized biosimilar version of its core renal anemia treatment Nesp (darbepoetin alfa)...read more